Patient Reported Outcomes Based on EQ-5D-5L Questionnaires in Head and Neck Cancer Patients
PO-1242
Abstract
Patient Reported Outcomes Based on EQ-5D-5L Questionnaires in Head and Neck Cancer Patients
Authors: Tanja Sprave1, Eleni Gkika2, Anca-Ligia Grosu2, Raluca Stoian2
1University Hospital of Freiburg, Radiation Oncology, Freiburg im Breisgau, Germany; 2University of Freiburg, Department of Radiation Oncology, Freiburg, Germany
Show Affiliations
Hide Affiliations
Purpose or Objective
Health economic comparisons of various therapies are often based on health-related quality of life (HRQOL) using EQ-5D questionnaires within the framework of clinical trials. This real-world study evaluates the patient reported outcomes (PROs)-based HRQOL of head-and-neck (H&N) cancer patients undergoing modern radiotherapy (RT) to reflect PRO trajectories.
Material and Methods
All H&N cancer patients treated in our clinic between July 2019 and December 2020 who completed the self-reported validated EQ-5D-5L questionnaire (health state index (HI) and Visual Analog Scale (VAS)) at baseline, end of radiotherapy, and at each respective follow up (FU) were included. Descriptive analysis of clinical and sociodemographic data, the frequency and level of each dimension was conducted. To assess the significance of therapy-induced HRQOL changes within and between the group, a distribution-based approach was used.
Results
Altogether, 366 participants completed a total of 565 questionnaires. For the whole cohort, HI at baseline was 0.804 (±0.208), at RT completion was 0.830 (±0.162), at the first follow-up was 0.812 (±0.205), and at the second follow-up was 0.769 (±0.224). The respective VAS values were 62.06 (±23,94), 66.73 (±82.20), 63.30 (±22.74), and 65.48 (±23.39). Females showed significantly lower HI values compared to males only at baseline (p=0.034). Significantly lower HI values were also seen in patients with definitive RT as compared to adjuvant RT at baseline (p=0.023), the second follow-up (p=0.047), and the third follow-up (p=0.010). As compared to outpatients, inpatients had significantly lower HI values at RT completion (p=0.017), the second follow-up (p=0.007), and the third follow-up (p=0.031). Subgroup analyses by age (<65 vs. ≥65) and smoking status (smokers vs. non-smokers) showed no difference at any time points.
Conclusion
PROs demonstrated detectability of time- and between-and within-groups-specific therapy-induced HRQOL changes. A further detailed exploration of EQ-5D-5L responsiveness for H&N cancer patients is required.